Increased biliary secretion and loss of hepatic glutathione in rat liver after nifurtimox treatment.
Treatment of rats with nifurtimox, a nitrofuran derivative widely used for the treatment of Chagas' disease, induced a time- and dose-dependent depletion of liver glutathione, maximal effects being obtained with 200 mg nifurtimox/kg body weight. Extra release of both oxidized (GSSG) and reduced (GSH) glutathione into bile contributed to this depletion. Glutathione excretion into bile accounted for only part of liver glutathione loss, thus indicating that, in addition to the GSH-peroxidase reaction (resulting in GSSG generation), other glutathione-related processes were involved in nifurtimox detoxification. Bile flow, bile salt excretion, liver lipid conjugated diene content, liver glutathione reductase and glutathione peroxidase activities, and serum alanine aminotransferase (ALAT) activity were not affected by the nifurtimox treatment, thus ruling out widespread damage of the liver cell by nifurtimox. Nevertheless, the extra GSH release in the nifurtimox-treated rats may indicate an alteration of the hepatocyte membrane.
D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D001646:Bile / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism*; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D008054:Lipid Peroxides / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D009547:Nifurtimox / Q000494:pharmacology*; D009581:Nitrofurans / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D008054:Lipid Peroxides; D009581:Nitrofurans; D005979:Glutathione Peroxidase; D005980:Glutathione Reductase; D000410:Alanine Transaminase; D005978:Glutathione; D009547:Nifurtimox